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GUEST EDITORIAL
Has chemotherapy proved itself in head and neck cancer?
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Cancers of the head and neck, which include tumours of the
upper air and food passages, constitute an important group
both numerically and epidemiologically, quite apart from the
exceptional challenges they pose in management.
Improvements in dental and oral hygiene, coupled with
lower alcohol and cigarette consumption, have led to a fall-
ing incidence, but there are some sites, including oral cavity
and oropharynx, in which the frequency among younger
subjects is rising. Overall these tumours account for approx-
imately 4% of all cancers and 3% of UK cancer deaths.
Despite improvements over the past 30 years in both diag-
nosis and management by surgery and/or radical radio-
therapy, the long-term survival has not appreciably altered.
Although early (T, or T2) tumours, particularly in the larynx
or oral cavity, carry an excellent prognosis, many patients
present with more advanced disease, in which the likelihood
of cure decreases with increasingly advanced 'T' stage and
even more sharply with increasing involvement (size and
fixity) of regional lymph nodes (Million et al., 1985).
The majority of head and neck tumours are typical squa-
mous cell carcinomas, of various degrees of differentiation.
Response to a wide variety of chemotherapeutic agents has
been documented over the past 20 years, closely paralleling
the frequency and degree of responsiveness seen in squamous
cancers at other sites such as the lung and cervix (Hong &
Bromer, 1983). Active agents include cytotoxic drugs from
several categories, including anti-folate anti-metabolites such
as methotrexate, with response rates of 30-40% (Bertino et
al., 1975), anti-tumour antibiotics (e.g. bleomycin 30% and
doxorubicin 20%) and pyrimidine anti-metabolites such as
fluorouracil (15% overall response), as well as cisplatin and
carboplatin (Wittes et al., 1977; de Andres Basauri et al.,
1986). Although most responses are incomplete and of brief
duration, combinations of these agents undoubtedly yield a
higher response rate, as high as 75% or greater for combina-
tions ofdrugs such as methotrexate, bleomycin and vinblastine
(Hong & Bromer, 1983). Unfortunately, however, remission
duration remains short, and cure is never seen with
chemotherapy alone. Furthermore, the toxicity of multidrug
regimes is high, particularly since many patients suffer from
other concomitant conditions including poor oral hygiene and
nutritional state, high alcohol intake and chronic respiratory
problems. Many believe that chemotherapy should not be
routinely used in such patients (Tannock & Browman, 1986).
Despite these difficulties, a number of groups have
attempted to use chemotherapy in patients with poor prog-
nosis advanced disease, either as induction therapy before
local treatment, or simultaneously with radical radiotherapy
(Gupta et al., 1987; SECOG Participants, 1986; Vokes et al.,
1989). The head and neck group at Christie Hospital, Man-
chester, recently published results from a large prospectively
randomised study in which radical radiotherapy, their stan-
dard approach for advanced carcinomas, was compared with
the same treatment, but with two pulses (100 mg m 2) of
single agent methotrexate given at the start (day 0) and half
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way through (day 14) the course of radiotherapy, with folinic
acid rescue in a minority of patients who had raised
methotrexate levels at 24 h. In patients with advanced
oropharyngeal carcinomas, there was striking improvement
in local control from 40% at 4 years (radiotherapy alone) to
75% for the combination (P = 0.0019). Overall survival was
also improved (20% vs 45%, P = 0.0089; medial follow-up 32
months). Trends in a similar direction were also noted, at
least for local control, at other sites, such as the larynx and
oral cavity, although not reaching statistical significance.
Since the oropharyngeal tumours were the largest single
group, the control and survival rates in the whole group were
better with single agent methotrexate than without (local
control P = 0.016; survival P = 0.075).
The authors concluded that 'synchronous' chemotherapy
with methotrexate was of value, and noted a reduction in the
need for salvage surgery (primary site resection) from 15% of
control cases to 4.5% in the methotrexate group. No addi-
tional side-effects were encountered. A further study from the
SECOG group gave similar results in patients with advanced
disease, although in a study design employing synchronous
chemotherapy (SECOG participants, 1986) using VBMF
(vincristine, bleomycin, methotrexate and fluorouracil) to-
gether with radical dose radiotherapy, versus the same regi-
men but with a 'sequential' timing, i.e. with the chemo-
therapy given before and subsequent to an unbroken course
of radiotherapy, and not 'synchronously' as in the other
group and in the Manchester approach. This prospectively
randomised study recruited 270 patients (SECOG I), but the
study design did not include a radiotherapy control arm until
a second study (SECOG II) was started 6 years ago (Feb-
ruary 1984), which has now recruited 240 patients (Tobias,
1988). Two interesting results have been the demonstration of
superior disease-free survival for synchronous chemotherapy
in patients with advanced laryngeal carcinoma, with a corres-
ponding reduction in the need for salvage surgery at this site;
and the suggestion from preliminary analysis of SECOG II
that administration of synchronous chemotherapy reduced
the need for salvage surgery below the rate noted in the
radiotherapy control arm (unpublished results), closely paral-
leling the Manchester observations. Despite the widely held
view that effective salvage surgery is not technically feasible
in patients who have previously undergone intensive com-
bination chemo-radiotherapy, the SECOG experience is quite
different (Grant et al., 1989; SECOG Participants, 1990). The
earlier of these reports described a total of 91 operative
procedures in a group of 267 patients treated in this way,
reporting a 10% operative mortality and overall 5 year sur-
vival rate (probable cures) of 20% in patients who were
clearly beyond non-surgical treatment.
Other groups have also reported encouraging results for
combination chemo-radiotherapy. A recent report from Yale
(Weissberg et al., 1989) randomised 120 patients with ad-
vanced head and neck cancer to undergo radical irradiation
with or without the addition of mitomycin C which was
given at least once, at a dose of 15 mgm-2 on the fifth day
of the radiotherapy and in some cases, on a second occasion
6 weeks later. Acute and chronic normal tissue reactions were
equal in the two groups and the 5 year disease-free survival
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was clearly better in the combination group (75% vs 49%).
No difficulties with surgical resection were encountered, in-
deed several patients underwent planned operations, and the
combination of chemo-radiotherapy with planned surgery
seemed particularly successful, with no reported local recur-
rences in this subgroup.
Several smaller uncontrolled studies have been reported,
with an increasing trend towards combination chemotherapy
often involving cisplatin and 5-fluorouracil following the
demonstration of high activity of this combination (Al Sarraf
et al., 1980; Kish et al., 1985; Taylor et al., 1985). For
example, Taylor and colleagues recently reported improved
response duration and survival (though not absolute response
rates) in a group of 53 patients treated with radical irradia-
tion and combined cisplatin/fluorouracil chemotherapy (Tay-
lor et al., 1989). Both this and the smaller study by Vokes et
al. (1989) are difficult to evaluate because of small population
size, heterogeneity of treatment and the use of historic con-
trols. In an accompanying editorial, the author noted that
'innovative approaches from pilot trials must withstand the
rigour of randomised trials before becoming the new stan-
dard of care' (Jacobs, 1989).
Despite over a decade of intensive attempts to use adju-
vant chemotherapy in head and neck cancer, considerable
doubt remains as to the true value of this approach. Chemo-
therapy, now frequently used in the USA as an adjuvant to
local treatment with radiotherapy and/or surgery, remains
less widely employed in the UK. Elsewhere in this issue,
Stell's comprehensive review provides a sobering overview of
its achievements to date. A number of interesting points
emerge, chiefly of course the dispiriting result that although
chemotherapy appears active in head and neck carcer, the
overall benefit is small, and in some circumstances offset by
toxicity. No single study was large enough to detect the
benefit with confidence. On the positive side, synchronous
treatment with chemotherapy and radiotherapy appeared to
be of value; as, for example, in both the Christie Hospital
and Yale University studies described in detail above. One
encouraging observation is the reduction in the rate of loco-
regional failure in the chemotherapy groups, particularly im-
portant in head and neck cancer where local failure generally
requires major and indeed hazardous salvage surgery. It is
clear that less toxic forms of chemotherapy have to be
devised since a good deal of potential benefit appeared to
have been lost as a result of treatment related deaths.
With the dismal results of treatment for advanced car-
cinoma of the head and neck, coupled with the large number
of primary sites, the evidence of response to a variety of
treatments and the relative infrequency of cases within single
departments, it seems clear that further randomised large
scale studies are urgently required, to assess the roles of
differing treatment combinations. The United Kingdom Co-
ordinating Committee for Cancer Research (UKCCCR) has
recognised this need and launched a new study in which,
once again, the possible benefit of chemotherapy has been
defined as the chief question. Patients requiring radiotherapy,
either as primary treatment or subsequent to surgical resec-
tion, will be prospectively randomised to receive chemo-
therapy or not. The study is of a 'factorial' type, to allow
powerful statistical analysis of the treatment groups. These
are: radical irradiation (RT) alone; RT plus two courses of
'synchronous' chemotherapy (i.e. given during the co-urse of
RT); RT and two courses of 'adjuvant' chemotherapy (i.e.
given after completion of the RT) or RT plus both syn-
chronous and adjuvant chemotherapy (total four courses).
Eligible patients who have undergone primary surgery will be
randomised to receive postoperative RT alone, or RT plus
two courses of chemotherapy. Induction chemotherapy (pre-
irradiation) is not being used, consistent with Stell's finding
that treatment of this type was ineffective.
Centres may choose which kind of chemotherapy to offer,
but will be encouraged to use single agent methotrexate as
described by Gupta et al. (1987), a simplified (it is hoped
outpatient based) SECOG-style VBMF or a combination of
cisplatin and 5-fluorouracil. Each centre would choose for
itself and keep to that decision, using one of the three
regimens throughout the study period. In effect, therefore,
the UKCCCR has taken a pragmatic view and the study is
effectively a planned prospectively randomised overview of
chemotherapy, a type of study which has provided critically
important data in other tumour types. Although there will be
no direct comparison between single agent and combination
chemotherapy, or between patients undergoing radiotherapy
alone or with surgical resection as part of the initial manage-
ment, such comparisons, made informally on the data,
should be of considerable interest.
Although it is perhaps unlikely that a major survival
benefit from chemotherapy will be demonstrated, the clear
evidence of improved disease-free survival, with consequent
reduction in the need for major and mutilating operations
makes this trial most welcome, quite apart from the unusual
achievements of bringing together major groups from Man-
chester, London, Edinburgh and other large centres which all
have differing approaches but have chosen to unite their
efforts for this study. If accrual is as expected, this could be
the first of many national studies in head and neck cancer.
Further details of the new study are available from Jean
Mossman, UKCCCR, MRC Head Office, Room 1, Second
Floor, Africa House, 64-78 Kingsway, London WC2B 6BG
(telephone: 071-269 3548; fax: 071-269 3439).
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